P-glycoprotein Mediates Ceritinib Resistance in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer

P-glycoprotein Mediates Ceritinib Resistance in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer

The anaplastic lymphoma kinase (ALK) fusion oncogene is observed in 3%–5% of non-small cell lung cancer (NSCLC). Crizotinib and ceritinib, a next-generation ALK tyrosine kinase inhibitor (TKI) active against crizotinib-refractory patients, are clinically available for the treatment of ALK-rearranged...

Full description

Bibliographic Details
Main Authors: Ryohei Katayama, Takuya Sakashita, Noriko Yanagitani, Hironori Ninomiya, Atsushi Horiike, Luc Friboulet, Justin F. Gainor, Noriko Motoi, Akito Dobashi, Seiji Sakata, Yuichi Tambo, Satoru Kitazono, Shigeo Sato, Sumie Koike, A. John Iafrate, Mari Mino-Kenudson, Yuichi Ishikawa, Alice T. Shaw, Jeffrey A. Engelman, Kengo Takeuchi, Makoto Nishio, Naoya Fujita
Format: Article
Language:English
Published: Elsevier 2016-01-01
Series:EBioMedicine
Subjects:
ALK
Tyrosine kinase
Resistance
Ceritinib
Crizotinib
P-glycoprotein
Online Access:http://www.sciencedirect.com/science/article/pii/S2352396415302425

Internet

http://www.sciencedirect.com/science/article/pii/S2352396415302425

Similar Items